Primary TBE Vaccination for the Elderly

Status Not yet recruiting

Clinical Trial Summary

Tick-borne Encephalitis (TBE) can be prevented by vaccine. Vaccine failure, defined as a case of TBE regardless of previous vaccination, has been described and seems to be more predominant with increasing age, suggesting a less effective immune response following with increasing age. In fact previous studies has shown a reduced antibody response in elderly individuals compared to younger when vaccinated against TBE. As a result, in Sweden, an extra vaccine dose has been recommended during the primary vaccine schedule to individuals > 50 years of age. This alternative vaccine schedule has not been tested. The investigator aim to test if an extra vaccine dose in the primary vaccine schedule for those > 50 years of age improves the immune response and offers a corresponding immunity to younger individuals following TBE vaccination.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04573205
Study type	Interventional
Source	Region Örebro County
Contact	Anja Rosdahl
Phone	+46196021157
Email	anja.rosdahl@regionorebrolan.se
Status	Not yet recruiting
Phase	Phase 4
Start date	January 2024
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04460235` - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma	Phase 4
Recruiting	`NCT04543877` - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study	Early Phase 1
Completed	`NCT00401505` - Rubella Susceptibility in Multiparous Women
Recruiting	`NCT05054621` - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule	Phase 2
Completed	`NCT05083065` - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Recruiting	`NCT05085145` - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV	Phase 4
Completed	`NCT05046548` - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19	Phase 1/Phase 2
Completed	`NCT01961947` - Study of ASP7374, Cell-culture-derived Influenza Vaccine	Phase 3
Completed	`NCT01961960` - A Study to Evaluate Intramuscular ASP7374	Phase 3
Completed	`NCT00401700` - Influenza Vaccine Postpartum Questionnaire
Completed	`NCT03300050` - Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine	Phase 1
Completed	`NCT01015703` - Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers	Phase 1
Completed	`NCT00560066` - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions	Phase 4
Active, not recruiting	`NCT05099965` - Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)	Phase 2
Recruiting	`NCT04638985` - Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR	Phase 4
Recruiting	`NCT06136832` - Pneumonia Vaccine Education Intervention Study	N/A
Active, not recruiting	`NCT04741828` - Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian	Phase 2/Phase 3
Completed	`NCT05083039` - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Completed	`NCT03714737` - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese	Phase 3
Completed	`NCT04664309` - Understanding Immunity to the COVID-19 Vaccines